Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

ves of women with advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each success helps lay the foundation for the next step forward," said William M. Burns, CEO Division Roche Pharmaceuticals. "These results show that we are making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating disease at all stages," he added.

    Presentation of Data

    Herceptin

    Gianni L et al  Neoadjuvant trastuzumab in patients with   Friday 12th,
                    HER2-positive locally advanced breast      December
                    cancer: primary efficacy analysis of the   09:30 hrs
                    NOAH trial                                 General
                                                               Session 3
                                                               (Hall D)

    Xeloda

    Joensuu H et    Significant improvement in                 Sunday 14th,
    al. for The     recurrence-free survival (RFS)             December
    Finnish Breast  when capecitabine (X) is                   11:45 hrs
    Cancer Group    integrated into docetaxel (T)              General
                    5-FU + epirubicin + cyclophosphamide       Session 7
                    (CEF) adjuvant therapy for high-risk
                    early breast cancer (BC): interim
                    analysis of the FinXX-trial.

    Avastin

    Smith IE et al  Primary analysis of study MO19391, an      Saturday
                    open-label safety study of bevacizumab     13th,
                    plus taxane-based therapy as 1st-line      December
                    treatment of patients with locally         07:00 hrs
                    recurrent or metastatic breast cancer.     Poster
                                                               Session 4

'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
(Date:7/30/2014)... 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), ... the cannabis testing and education markets, announced today that ... affairs not previously disclosed or, to its knowledge, any ... action. "We have noticed unusual price and ... trading days," said Steve Barbee , CEO of ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), ... and gastroenterology markets, today announced that it has entered ... a new Phase II development product. The Company has ... Injection and is evaluating the product for the treatment ...
... Inc. (NYSE: CRY ), an implantable biological ... that 2011 first quarter financial results will be released ... Company will hold a teleconference call and live webcast ... followed by a question and answer session hosted by ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results 2
(Date:7/30/2014)... Imprivata ® (NYSE: IMPR), ... secure communications solutions for the healthcare industry, today ... most widely selected single sign-on (SSO) solution amongst ... medical records (EMR) systems with a 51 percent ... in the last 12 months), according to HIMSS ...
(Date:7/30/2014)... obese people have a genetic mutation that seems to ... they see food, researchers report. Gaining a better ... and gratification at the sight of high-calorie foods like ... the scientists suggested. More than one-third of U.S. ... a combination of overeating, a lack of physical activity ...
(Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... As the controversy surrounding the use ... continues to grow, Bernstein Liebhard LLP notes that another ... a ban on uterine morcellation. According to a report ... leiomyosarcoma following a hysterectomy that involved the use of ... the aggressive cancer had progressed to Stage 4. Ms. ...
Breaking Medicine News(10 mins):Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... , , , BOISE, Idaho, Dec. 28 The research shows, ... bulge becomes a main priority for those setting New Year resolutions ... war; individuals must be prepared to make lifestyle changes starting with ... Light offer two ways to indulge while working off and managing ...
... , ... Absolutely Public Relations reviews 2009 key media placement results, plus celebrates client and ... anniversary in business, representing the Colorado Cleantech Industry Association, Bell Aquaculture, Colorado BioScience ... , ...
... , WASHINGTON, Dec. 28 CAQH® announced today that ... are the first national health plans to earn certification ... on Operating Rules for Information Exchange® (CORE) Phase II ... in the ongoing development of the CORE rules, which ...
... 28, 2009 -- Children regularly exposed to tobacco smoke ... in adulthood. This finding by researchers at Columbia University,s ... may not recover completely from the effects of early-life ... in the December 2009 American Journal of Epidemiology ...
... , ASHBURN, Va., Dec. ... data capture and enterprise search solutions , today ... France, has selected the company,s Brainware Distiller(TM) solution to automate ... 150 countries and processes hundreds of thousands of invoices and ...
... ... Jack Canfield, Dr. Joe Vitale & Marci Shimoff, Jennifer Nicole Lee is ... and enlightens audiences worldwide with her highly anticipated book "The Mind, Body ... story who has become one of the world,s most accomplished fitness experts. ...
Cached Medicine News:Health News:Make Your 2010 Resolution and Chill Out with Crystal Light Frozen Treats 2Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 2Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 3Health News:Denver Public Relations Consulting Firm, Absolutely Public Relations, Recaps 2009 Key Media Placement Results, Plus Client and Company Milestones 4Health News:Aetna and WellPoint Achieve CORE Phase II Certification 2Health News:Aetna and WellPoint Achieve CORE Phase II Certification 3Health News:Exposure to tobacco smoke in childhood home associated with early emphysema in adulthood 2Health News:bioMerieux Selects Brainware to Automate Accounts Payable 2Health News:bioMerieux Selects Brainware to Automate Accounts Payable 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 2Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 4
... Type 300 ,Oblique 45, ,Type 330 ... illumination by setting the illumination between ... be ideal for use in ophthalmology ... other conventional compact microscope can; an ...
... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
... cost-effective line of compact CO2 systems available ... 30 or 40 watts combines portability ... extremely accurate laser beam, as well as ... advantageous for small operating theatres and are ...
... PhotoLightFACIAL facial skin treatment, vascular ... Incorporates a wide range ... multiple hand pieces and large ... the most flexibility. Compact ...
Medicine Products: